Go Pro
→ Your 10X AI demo is starting… (From TradeSmith) (Ad)tc pixel Free GDTC Stock Alerts

CytoMed Therapeutics (GDTC) Competitors

CytoMed Therapeutics logo
$0.95 +0.10 (+12.30%)
Closing price 03:59 PM Eastern
Extended Trading
$0.95 +0.00 (+0.01%)
As of 05:14 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

GDTC vs. APLM, DYAI, LTRN, BYSI, and ALGS

Should you buy CytoMed Therapeutics stock or one of its competitors? CytoMed Therapeutics's main competitors and comparable companies include Apollomics (APLM), Dyadic International (DYAI), Lantern Pharma (LTRN), BeyondSpring (BYSI), and Aligos Therapeutics (ALGS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does CytoMed Therapeutics compare to Apollomics?

Apollomics (NASDAQ:APLM) and CytoMed Therapeutics (NASDAQ:GDTC) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, valuation, risk, media sentiment, dividends and analyst recommendations.

CytoMed Therapeutics has lower revenue, but higher earnings than Apollomics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Apollomics$8.50M5.83-$10.94MN/AN/A
CytoMed Therapeutics$250K44.90-$3.10MN/AN/A

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Apollomics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
CytoMed Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

19.1% of Apollomics shares are owned by institutional investors. Comparatively, 0.0% of CytoMed Therapeutics shares are owned by institutional investors. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Apollomics had 1 more articles in the media than CytoMed Therapeutics. MarketBeat recorded 3 mentions for Apollomics and 2 mentions for CytoMed Therapeutics. CytoMed Therapeutics' average media sentiment score of 1.43 beat Apollomics' score of 0.62 indicating that CytoMed Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Apollomics Positive
CytoMed Therapeutics Positive

Company Net Margins Return on Equity Return on Assets
ApollomicsN/A N/A N/A
CytoMed Therapeutics N/A N/A N/A

Apollomics has a beta of 1.46, suggesting that its stock price is 46% more volatile than the broader market. Comparatively, CytoMed Therapeutics has a beta of 0.04, suggesting that its stock price is 96% less volatile than the broader market.

Summary

Apollomics beats CytoMed Therapeutics on 4 of the 7 factors compared between the two stocks.

How does CytoMed Therapeutics compare to Dyadic International?

CytoMed Therapeutics (NASDAQ:GDTC) and Dyadic International (NASDAQ:DYAI) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, media sentiment, valuation, institutional ownership, risk, profitability, analyst recommendations and dividends.

CytoMed Therapeutics has a beta of 0.04, indicating that its share price is 96% less volatile than the broader market. Comparatively, Dyadic International has a beta of 1.12, indicating that its share price is 12% more volatile than the broader market.

0.0% of CytoMed Therapeutics shares are owned by institutional investors. Comparatively, 28.0% of Dyadic International shares are owned by institutional investors. 20.9% of Dyadic International shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Dyadic International has a consensus target price of $3.00, indicating a potential upside of 287.05%. Given Dyadic International's stronger consensus rating and higher possible upside, analysts plainly believe Dyadic International is more favorable than CytoMed Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
CytoMed Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Dyadic International
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.33

In the previous week, Dyadic International had 10 more articles in the media than CytoMed Therapeutics. MarketBeat recorded 12 mentions for Dyadic International and 2 mentions for CytoMed Therapeutics. CytoMed Therapeutics' average media sentiment score of 1.43 beat Dyadic International's score of 0.11 indicating that CytoMed Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
CytoMed Therapeutics Positive
Dyadic International Neutral

CytoMed Therapeutics has higher earnings, but lower revenue than Dyadic International.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CytoMed Therapeutics$250K44.90-$3.10MN/AN/A
Dyadic International$3.09M9.14-$7.36M-$0.23N/A

CytoMed Therapeutics has a net margin of 0.00% compared to Dyadic International's net margin of -201.43%. CytoMed Therapeutics' return on equity of 0.00% beat Dyadic International's return on equity.

Company Net Margins Return on Equity Return on Assets
CytoMed TherapeuticsN/A N/A N/A
Dyadic International -201.43%-2,920.31%-84.77%

Summary

Dyadic International beats CytoMed Therapeutics on 8 of the 14 factors compared between the two stocks.

How does CytoMed Therapeutics compare to Lantern Pharma?

Lantern Pharma (NASDAQ:LTRN) and CytoMed Therapeutics (NASDAQ:GDTC) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, dividends, earnings, risk and media sentiment.

CytoMed Therapeutics' return on equity of 0.00% beat Lantern Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Lantern PharmaN/A -198.34% -129.08%
CytoMed Therapeutics N/A N/A N/A

CytoMed Therapeutics has higher revenue and earnings than Lantern Pharma.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lantern PharmaN/AN/A-$17.12M-$1.45N/A
CytoMed Therapeutics$250K44.90-$3.10MN/AN/A

28.6% of Lantern Pharma shares are owned by institutional investors. Comparatively, 0.0% of CytoMed Therapeutics shares are owned by institutional investors. 8.5% of Lantern Pharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Lantern Pharma has a beta of 2.34, suggesting that its stock price is 134% more volatile than the broader market. Comparatively, CytoMed Therapeutics has a beta of 0.04, suggesting that its stock price is 96% less volatile than the broader market.

In the previous week, Lantern Pharma had 2 more articles in the media than CytoMed Therapeutics. MarketBeat recorded 4 mentions for Lantern Pharma and 2 mentions for CytoMed Therapeutics. CytoMed Therapeutics' average media sentiment score of 1.43 beat Lantern Pharma's score of 0.94 indicating that CytoMed Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Lantern Pharma Positive
CytoMed Therapeutics Positive

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Lantern Pharma
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
CytoMed Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Summary

CytoMed Therapeutics beats Lantern Pharma on 5 of the 9 factors compared between the two stocks.

How does CytoMed Therapeutics compare to BeyondSpring?

CytoMed Therapeutics (NASDAQ:GDTC) and BeyondSpring (NASDAQ:BYSI) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, media sentiment, dividends, valuation and earnings.

0.0% of CytoMed Therapeutics shares are held by institutional investors. Comparatively, 40.3% of BeyondSpring shares are held by institutional investors. 29.3% of BeyondSpring shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

BeyondSpring has higher revenue and earnings than CytoMed Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CytoMed Therapeutics$250K44.90-$3.10MN/AN/A
BeyondSpring$1.75M19.72-$1.01M-$0.14N/A

Company Net Margins Return on Equity Return on Assets
CytoMed TherapeuticsN/A N/A N/A
BeyondSpring N/A N/A -14.00%

CytoMed Therapeutics has a beta of 0.04, meaning that its share price is 96% less volatile than the broader market. Comparatively, BeyondSpring has a beta of 0.48, meaning that its share price is 52% less volatile than the broader market.

In the previous week, BeyondSpring had 4 more articles in the media than CytoMed Therapeutics. MarketBeat recorded 6 mentions for BeyondSpring and 2 mentions for CytoMed Therapeutics. CytoMed Therapeutics' average media sentiment score of 1.43 beat BeyondSpring's score of 0.63 indicating that CytoMed Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
CytoMed Therapeutics Positive
BeyondSpring Positive

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
CytoMed Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
BeyondSpring
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Summary

BeyondSpring beats CytoMed Therapeutics on 6 of the 9 factors compared between the two stocks.

How does CytoMed Therapeutics compare to Aligos Therapeutics?

Aligos Therapeutics (NASDAQ:ALGS) and CytoMed Therapeutics (NASDAQ:GDTC) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, earnings, dividends, analyst recommendations, valuation and media sentiment.

60.4% of Aligos Therapeutics shares are held by institutional investors. Comparatively, 0.0% of CytoMed Therapeutics shares are held by institutional investors. 7.8% of Aligos Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

CytoMed Therapeutics has a net margin of 0.00% compared to Aligos Therapeutics' net margin of -241.01%. CytoMed Therapeutics' return on equity of 0.00% beat Aligos Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Aligos Therapeutics-241.01% -160.72% -92.30%
CytoMed Therapeutics N/A N/A N/A

CytoMed Therapeutics has lower revenue, but higher earnings than Aligos Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aligos Therapeutics$2.19M19.63-$24.19M-$7.30N/A
CytoMed Therapeutics$250K44.90-$3.10MN/AN/A

In the previous week, Aligos Therapeutics had 14 more articles in the media than CytoMed Therapeutics. MarketBeat recorded 16 mentions for Aligos Therapeutics and 2 mentions for CytoMed Therapeutics. CytoMed Therapeutics' average media sentiment score of 1.43 beat Aligos Therapeutics' score of 0.25 indicating that CytoMed Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Aligos Therapeutics Neutral
CytoMed Therapeutics Positive

Aligos Therapeutics has a beta of 2.31, meaning that its stock price is 131% more volatile than the broader market. Comparatively, CytoMed Therapeutics has a beta of 0.04, meaning that its stock price is 96% less volatile than the broader market.

Aligos Therapeutics presently has a consensus target price of $38.50, indicating a potential upside of 458.78%. Given Aligos Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Aligos Therapeutics is more favorable than CytoMed Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aligos Therapeutics
1 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.86
CytoMed Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Summary

Aligos Therapeutics beats CytoMed Therapeutics on 9 of the 15 factors compared between the two stocks.

Get CytoMed Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for GDTC and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GDTC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

GDTC vs. The Competition

Export
MetricCytoMed TherapeuticsBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$10M$3.71B$6.98B$13.04B
Dividend YieldN/A3.76%2.58%10.72%
P/E RatioN/A10.68269.8625.30
Price / Sales44.901,308.25601.81101.06
Price / CashN/A103.0170.5350.75
Price / Book2.1117.4913.086.33
Net Income-$3.10M-$13.32M$3.45B$347.70M
7 Day Performance14.05%1.74%1.12%1.07%
1 Month Performance-4.54%1.60%1.79%1.03%
1 Year Performance-46.39%56.43%67.69%20.77%

CytoMed Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
GDTC
CytoMed Therapeutics
0.9328 of 5 stars		$0.95
+12.3%		N/A-52.2%$10M$250KN/AN/A
APLM
Apollomics
1.316 of 5 stars		$17.60
+3.5%		N/A+208.0%$38.72M$8.50MN/A45
DYAI
Dyadic International
3.2123 of 5 stars		$1.01
-1.4%		$3.00
+198.2%		-6.1%$36.66M$1.67MN/A7
LTRN
Lantern Pharma
0.3131 of 5 stars		$2.87
+3.1%		N/A-44.7%$36.56MN/AN/A20
BYSI
BeyondSpring
0.1491 of 5 stars		$0.85
-2.2%		N/A-50.2%$34.99M$1.75MN/A80

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:GDTC) was last updated on 8/14/2026 by MarketBeat.com Staff.
From Our Partners
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
Trump’s New Currency Reset
Trump is launching a new $250 bill - but that may be a distraction. Behind the scenes, Executive Order 14241 i...
Porter & Company | Sponsoredtc pixel
They didn't warn anyone in 1971. This time someone is warning you.
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Buy These Stocks Before August 31st
Keith Kaplan has invested $17 million into his own AI research platform, now used by 180,000 investors worldwi...
TradeSmith | Sponsoredtc pixel
Central banks bought 710 tonnes - this fund pays monthly
Gold is hitting new highs, fueled by tariffs and record central bank demand - 710 tonnes per quarter. JPMorgan...
Investors Alley | Sponsoredtc pixel
Wall Street is staring at the wrong AI trade
Anthropic just signed a 9.1 billion dollar, 20 year data center agreement covering 191 megawatts of capacity, ...
The Oxford Club | Sponsoredtc pixel
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...
Profits Run | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel